Adebrelimab combined with oral etoposide for older patients and patients with poor performance status In small cell lung cancer: A multicenter, open-label, phase II clinical study.

作者：F Q Liu, Meng Hong Xue, Yan Zhang, Sun H, Linlin Liu, Xiao Chen, Liying Zhang, 刘敬东, Xin Zhou · 发表于：Journal of Clinical Oncology · 年份：2026 · DOI：10.1200/jco.2026.44.19_suppl.tps293 · 研究领域：Lung Cancer Research Studies、Neuroendocrine Tumor Research Advances、Lung Cancer Treatments and Mutations

TPS293 Background: Small cell lung cancer (SCLC) is a highly aggressive, high-grade neuroendocrine carcinoma characterized by rapid proliferation and early metastatic dissemination. Recent research has demonstrated that adebrelimab plus platinum-based chemotherapy have demonstrated promising anti-tumour activity in first-line treatment of SCLC in CAPSTONE-1 trial. However, a substantial proportion of patients—particularly older patients and those with poor performance status (ECOG PS ≥2) or significant comorbidities—cannot tolerate standard platinum-based regimens due to reduced tolerance to systemic therapy. In such cases, oral etoposide is an active single-agent option. Therefore, this study aims to evaluate the efficacy and safety of adebrelimab combined with oral etoposide as a first-line treatment for SCLC in older patients and those with poor performance status. Methods: In this multicenter, open-label, phase II trial, 47 patients with extensive-stage SCLC or limited-stage, diagnosed histologically or cytologically, and who are treatment-naive are anticipated to be enrolled. Key inclusion criteria are: age≥65 years, or an Eastern Cooperative Oncology Group performance status of 2 or 3, an expected life expectancy of at least 3 months, and adequate organ function, not indicated for curative surgery or chemoradiotherapy. Additionally, patients aged < 65 years with an ECOG PS of 0-1 may be considered if they have extensive comorbidities. Key exclusion criteria included ...